Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP
NCT02120196Phase 3Unknown
- Start
- Jan 2014
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in spontaneous bacterial peritonitis (SBP). Status: unknown.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT02120196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120196.